Skip to Main Content

++

INTRODUCTION

++

beractant (be-rak-tant)

Survanta

Classification

Therapeutic: anti-RDS agents

Pharmacologic: pulmonary surfactants

++
Indications
++

Treatment and prophylaxis of respiratory distress syndrome (RDS, hyaline membrane disease) in premature infants.

++
Action
++

Replaces endogenous pulmonary surfactant in premature infants, allowing normal surface activity in alveoli. Consists of natural bovine lung extract. Therapeutic Effects: Decreased incidence, mortality, and complications from RDS.

++
Adverse Reactions/Side Effects
++

Resp: oxygen desaturation (as a result of administration process). CV: transient bradycardia.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor oxygen saturation levels following administration. Notify physician or nursing staff immediately about a sudden decrease is oxygen saturation.

  • Assess heart rate, and report a sustained decrease in heart rate (bradycardia).

++
Interventions
++

  • When indicated, implement chest physical therapy interventions such as positioning, suctioning, and chest percussion/vibration to maintain respiratory function and augment drug effects in premature infants.

++
Pharmacokinetics
++

Absorption: Administered directly to site of action. Systemic absorption not known.

++

Distribution: Rapidly distributes to lung tissue.

++

Metabolism and Excretion: Enters surfactant pathways in which recycling and reutilization occur.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (improved oxygenation)

ROUTE ONSET PEAK DURATION
intratracheal within min unknown unknown

++
Contraindications/Precautions
++

Contraindicated in: No known contraindications.

++

Use Cautiously in: No known cautions. Nosocomial infections may be more common.

++
Interactions
++

Drug-Drug: None known.

++
Route/Dosage
++

Intratracheal (Infants, Premature): 100 mg phospholipids/kg birth weight (4 mL/kg birth weight); 4 doses may be given in first 48 hr of life, no closer than q 6 hr apart.

++
Availability
++

Intratracheal suspension: 25 mg phospholipid/mL—4-mL and 8-mL vials.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.